Advaxis’ Senior Science Team and Head Clinician to Participate in Science Update Conference Call

Q&A Session Extended To Field General Questions On Previously Undescribed Capabilities of Advaxis’ Platform Immunotherapy

NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)-- On the upcoming science conference call hosted by Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, excerpts from the presentation given on December 1, 2010 at the American Association of Cancer Research highlighting previously undescribed capabilities of Advaxis’ platform immunotherapy will be discussed by the Company’s science team. Insight into the Company’s clinical trial program will be addressed by Advaxis’ new VP of Clinical Operations, Dr. Robert Petit.

Advaxis’ science team in attendance include: EVP of Science and Operations, Dr. John Rothman and senior scientists Drs. Anu Wallecha and Reshma Singh.

For those investors interested in participating in Advaxis’ 2010 Science Update conference call on Thursday, December 16, 2010 at 2:00 p.m. EST, please refer to the following information and RSVP as soon as practicable as there are a limited number of bridge lines available:

Dial-in: (domestic) 877- 681-3378; (international) 719-325-4750

Conference ID: 4878858

Playback: (domestic) 888-203-1112; (international) 719-457-0820

Replay Code: 4878858. Playback available until December 19, 2010 at 5:00 p.m. EST

RSVP: [email protected] by 1:00 p.m. EST, Thursday, December 16, 2010.

The call will be recorded and a link to the recoding will be posted on www.advaxis.com and the Company’s corporate portal on facebook on or before Thursday, December 23, 2010.

About Advaxis, Inc.

Advaxis is a biotechnology company developing proprietary, live, attenuated Listeria monocytogenes (Listeria) vaccines that deliver engineered tumor antigens, which stimulate multiple, simultaneous immunological mechanisms to fight cancer. Today, the Company has nine (9) distinct, cancer-fighting constructs in various stages of development, four (4) clinical trials – two (2) in progress and two (2) to be started – and two (2) Cooperative Research and Development Agreements (CRADA) with the National Cancer Institute and the Department of Homeland Security, respectively. The Company conducts direct and strategic collaborations with such recognized sites of excellence as the City of Hope, the Roswell Park Cancer Institute, the University of Pittsburgh and the University of British Columbia.

Advaxis’ technology was developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania and chairperson of Advaxis’ scientific advisory board. Please visit the Company’s portals: advaxis.com | facebook | twitter | LinkedIn.

Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company’s current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.



CONTACT:

Advaxis, Incorporated
Conrad F. Mir
Executive Director
732-545-1590 (Office)
732-545-1084 (FAX)
[email protected]
or
Diana Moore
Analyst
732-545-1590 (Office)
732-545-1084 (FAX)
[email protected]

KEYWORDS:   United States  North America  New Jersey

INDUSTRY KEYWORDS:   Health  Biotechnology  Oncology  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.